Cerca Biotech’s 2023 Highlights
2023 was a stand out year for Cerca Biotech. We doubled our team, added a major partner in Sysmex Europe, and were present at all the major congresses. At the same time, the pharmaceutical world took some big steps forward with defining trials in ADC and CDK 4/6 therapy, both of which have an inherent need for more reliable and reproducible testing for HER2 and Ki67 - which MammaTyper® can provide.
We look back on the work we have done this year around branding and marketing with pride. Our small but massively experienced team has pulled together to put MammaTyper® on the map in a way we could...